The authors of the original article, Clin Sci (Lond) (2023) 137 (9): 727-753, would like to correct their paper. The monoclonal antibody depemokimab described as anti-IL-5R, have been corrected to anti-IL5 in the following statement and in the revised Table 2 provided below.

Furthermore, benralizumab showed efficacy in patients with severe CRSwNP by decreasing nasal blockage score in a randomized placebo controlled study [229] Depemokimab, a long-acting anti-IL-5 monoclonal antibody, is currently being evaluated in phase III clinical trials in severe uncontrolled asthma with an eosinophilic phenotype (NCT04719832).

This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the Creative Commons Attribution License 4.0 (CC BY).